Notice of Allowability	Application No.	Applicant(s)
	09/880,503	CINES ET AL.
	Examiner	Art Unit
	Samuel W Liu	1653
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to 6-19-2004.		
2. X The allowed claim(s) is/are 1-2, 5-8, 11, 18, 22, 24-26, 28 and 54-55.		
3. The drawings filed on 13 June 2001 are accepted by the Examiner.		
 4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17,2(a)). * Certified copies not received: 		
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		complying with the requirements
5. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give	itted. Note the attached EXAMINER'es reason(s) why the oath or declara	S AMENDMENT or NOTICE OF tion is deficient.
6. CORRECTED DRAWINGS (as "replacement sheets") mus	at be submitted.	
(a) 🗌 including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) 🗌 hereto or 2) 🔲 to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in the	.84(c)) should be written on the drawir he header according to 37 CFR 1.121(c	ngs in the front (not the back) of
7. DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT	sit of BIOLOGICAL MATERIAL n FOR THE DEPOSIT OF BIOLOGICA	nust be submitted. Note the AL MATERIAL.
Attachment(s) 1. ☐ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☑ Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date 7-31-03 & 4-15-02 4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ⊠ Interview Summary Paper No./Mail Dat 8), 7. ⊠ Examiner's Amendn	e <u>6-24-04</u> .

Application/Control Number: 09/880,503

Art Unit: 1653

DETAILED ACTION

This Office action is in response to applicants' amendments filed 19 April 2004, which cancels claims 9, 12 and 14-17, and amends claims 1-2, 5, 7-9, 11, 15-16, 18, 22, 24-25, 2 and 54. The amendment indicated above has been entered.

The pending claims 1-2, 5-8, 10-11, 13 and 18-55 are therefore examined in this Office action.

EXAMINER'S AMENDMENT

An Examiner's Amendment to the record appears below. Should the change and/or additions be unacceptable to Applicant, an amendment may be filed as provided by 37 C.F.R. § 1.312. To ensure consideration of such an amendment, it MUST be submitted no latter than payment of the Issue Fee.

Authorization for this Examiner's Amendment was given in a telephone interview with Kathryn Doyle on June 24,2004. Applicants agree the Examiner proposed amendment to claims 3-5, 9-13 and 14-17, 19-21, 23, 27 and 29-53 (see below).

Amendments to the claim:

The pending claims 3-5, 9-13 and 14-17, 19-21, 23, 27 and 29-53 have been amended or canceled as follows. Please replace the previous claims with the claim shown below.

Claims 3-4 are deleted.

Claim 5 (*Twice amended*): After "said polypeptide", change "(LMW-uPA)" to "(low molecular weight domain of uPA)".

Claims 10, 13, 19-21, 23, 27 and 29-53 are deleted.

Conclusion: Claims 1-2, 5-8, 11, 18, 22, 24-26, 28 and 54-55 are allowable over the art of record.

Any comments considered necessary by applicants must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably Art Unit: 1653

accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Samuel Wei Liu, Ph.D. whose telephone number is (571) 272-0949. The Examiner can normally be reached daily except alternate Fridays from 8:30 A.M. to 5:30 P.M. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Christopher Low, can be reached at (571) 272-0951. The official fax number for Technology Center 1600 is (703) 308-4242. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

KAREN COCHRANE CARLSON, PH.D PRIMARY EXAMINER

Karer Cochane Carlsa PD

Samuel W. Liu, Ph.D. Art Unit 1653, Examiner

June 25, 2004

501